@BreastCaConnect BREAST CANCER CONNECT powered by COR2ED
BREAST CANCER CONNECT powered by COR2ED posts on X about watch, bc, data, check the most. They currently have [-----] followers and [---] posts still getting attention that total [-------] engagements in the last [--] hours.
Engagements: [-------] #
- [--] Week [-------] +121%
- [--] Month [---------] +4,876,282%
- [--] Months [---------] -27%
- [--] Year [---------] -14%
Mentions: [--] #
- [--] Week [--] +40%
- [--] Month [--] +450%
- [--] Months [--] +53%
- [--] Year [--] no change
Followers: [-----] #
- [--] Week [-----] +2.10%
- [--] Month [-----] +5.30%
- [--] Months [-----] +18%
- [--] Year [-----] +36%
CreatorRank: [-------] #
Social Influence
Social category influence stocks #2913 finance 1.94% technology brands 0.97% travel destinations 0.97%
Social topic influence watch 14.56%, bc 14.56%, data 14.56%, check 8.74%, testing 7.77%, future 6.8%, virtual 6.8%, study 6.8%, share 6.8%, update 6.8%
Top accounts mentioned or mentioned by @ptarantinomd @dradityabardia @stolaney1 @grasptweets @elisaagostinett @dfcibreastonc @waroncancer @javiercortesmd @hoperugo @oncbrothers @barbarapistill2 @ucsfcancer @jhaverikomal @myesmo @vumedi @matteolambe @fandremd @oncoalert @twooncdocs @dryakupergun
Top assets mentioned Spotify Technology (SPOT) Thermo Fisher Scientific Inc. (TMO)
Top Social Posts
Top posts by engagements in the last [--] hours
"Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification Breast cancer experts share their insights - highlights in this post 📹 Supported by an Independent Educational Grant from AstraZeneca"
X Link 2026-02-13T13:07Z [----] followers, 170K engagements
"Metastatic breast cancer: Understanding HER2-low and HER2-ultralow classification 📹 A novel therapeutic framework Breast cancer experts share their insights Supported by an Independent Educational Grant from AstraZeneca"
X Link 2026-02-03T16:25Z [----] followers, 242.6K engagements
"HER2+ metastatic breast cancer How can we manage TRAEs e.g. N+V/fatigue/ILD 📺 Video from Prof. @JavierCortesMD View/download the expert consensus BluePrint now: Supported by an Independent Educational Grant from AstraZeneca #MedEd #BCSM #MedTwitter https://cor2ed.com/breast-cancer-connect/programmes/adcs-her2-metastatic-breast-cancer-managing-adverse-events/media=0 https://cor2ed.com/breast-cancer-connect/programmes/adcs-her2-metastatic-breast-cancer-managing-adverse-events/media=0"
X Link 2026-02-06T08:26Z [----] followers, [---] engagements
"🚨🗣 The final episode of the 3-part #podcast series on #oralSERDs in ER+ #breastcancer is out now 🎧 In this episode the experts tackle two rare cases exploring the questions & challenges faced by both patients & healthcare professionals. #MedEd https://ow.ly/6s9k50PJXiM https://ow.ly/6s9k50PJXiM"
X Link 2023-09-11T14:02Z [----] followers, 871.1K engagements
"Missed #ESMO23 👇🏼👇🏼👇🏼 Here's a speedy summary of Adjuvant Endocrine Therapy in ER+ EBC presented at the conference🗣 https://x.com/Sameh_VuMedi/status/1721156941932806465utm_source=twitter&utm_medium=social&utm_content=b67f5688-914d-44db-b8c1-801c9b8418cc&utm_campaign=Twitter+Website+Traffic Check out Dr. Sara Tolaney @stolaney1 @DFCI_BreastOnc & Dr. Hope Rugo @hoperugo @UCSFCancer panel discussion on #ESMO23 early Breast Cancer updates and their impact on clinical practice #bcsm #breastcancer #eBC Full video on #VuMedi 👇 https://t.co/otZvh2joas https://t.co/g3iveoiRYV"
X Link 2023-11-07T08:15Z [----] followers, [----] engagements
"HER2+ metastatic breast cancer How can we manage TRAEs e.g. N+V/fatigue/ILD 📺 Video from Prof. @JavierCortesMD Supported by an Independent Educational Grant from AstraZeneca"
X Link 2026-02-06T11:12Z [----] followers, 631K engagements
"Metastatic #breastcancer: #MedEd resources Understanding HER2-low and HER2-ultralow classification in metastatic breast cancer A novel therapeutic framework From @OncBrothers & @jhaveri_komal 📹 Watch the full video/listen on Spotify or Apple/view the infographic: Supported by an Independent Educational Grant from AstraZeneca #MedEd #BCSM https://cor2ed.com/breast-cancer-connect/programmes/metastatic-breast-cancer-her2-low-ultralow-classification/media=2 https://cor2ed.com/breast-cancer-connect/programmes/metastatic-breast-cancer-her2-low-ultralow-classification/media=2"
X Link 2026-02-13T14:43Z [----] followers, [---] engagements
"💬#ADCs transformed #HER2+ advanced #BC treatment in the last decade. #T-DXd outperformed #T-DM1 but #T-DXd resistance poses challenges. Prioritizing research to tackle resistance is crucial as the field evolves rapidly. 👉Great review: #MedEd #bcsm https://ow.ly/fljO50PtSZ8 https://ow.ly/fljO50PtSZ8"
X Link 2023-08-09T09:00Z [----] followers, [----] engagements
"Phase [--] #TROPION-Breast01 trial hits its co-primary endpoint with promising results🎯⚡ 💊📊#Datopotamab deruxtecan (DS-1062a) demonstrates a notable improvement in PFS vs chemo in inoperable/metastatic HR+ HER2-low/HER2- cases. https://ow.ly/N9Vw50PP7Ph https://ow.ly/N9Vw50PP7Ph"
X Link 2023-09-26T11:52Z [----] followers, [----] engagements
"🚨Our animated video on treating metastatic #BC w/ Prof. Francois-Clement Bidard is here You will learn: ✔the importance of molecular characteristics ✔when to perform ESR1 mutation testing ✔current treatment options #MedEd https://ow.ly/QVHZ50PZkiw https://ow.ly/QVHZ50PZkiw"
X Link 2023-10-22T10:09Z [----] followers, 815.7K engagements
"Great presentation from Prof.Schmid 🔺Majority of stage [--] #TNBC should be treated with systemic therapy 🔺if ChT is given consider neoadjuvant therapy 🔺ADC +/- IO possible de-escalation strategy #MedED #ESMO23 #bcsm"
X Link 2023-10-23T13:50Z [----] followers, [----] engagements
"🚨What targetable mutations are you looking for in ER+ #mBC Join Prof. Valentina Guarneri on an interactive patient journey to explore treatment strategies & AE management for ER+/HER2- #mBC. Don't miss the clickable content along the way 👉 #MedEd https://ow.ly/jPFj50Q44rN https://ow.ly/jPFj50Q44rN"
X Link 2023-11-06T09:39Z [----] followers, 121.6K engagements
"Q2. In accordance with the recent ASCO [----] guidelines when and how would you test for an ESR1 mutation You have 48h to reply Cast your votes now #tweetorial @PTarantinoMD Only upon diagnosis Only post 1L progression None of the above At progression/recurrence Only upon diagnosis Only post 1L progression None of the above At progression/recurrence"
X Link 2023-11-15T14:22Z [----] followers, 34K engagements
""It's not just October for me; it's every day all year"🎗 Join an emotional journey w/ the 1st episode of our #breastcancer awareness series where untold stories unfold reminding us that: Breast Cancer doesn't end on the 31st of October @GRASPtweets #GRASPtweets #bcsm"
X Link 2023-11-27T10:16Z [----] followers, 220.3K engagements
"📑Explore the latest @myESMO Clinical Practice Guideline on #EarlyBreastCancer This comprehensive guide offers key recommendations and algorithms for diagnosis staging treatment and more. #MedEd #bcsm https://ow.ly/bPtx50QsSFb https://ow.ly/bPtx50QsSFb"
X Link 2024-01-25T10:01Z [----] followers, [---] engagements
"Join @PTarantinoMD as he recaps the latest breakthroughs and developments in breast cancer from the past year 🌍🔬 👇👇👇 #Meded #bcsm https://x.com/PTarantinoMD/status/1753124058407825823s=20&utm_source=twitter&utm_medium=social&utm_content=ce3dbc7e-ff47-4021-9aa6-2dda5d68274d&utm_campaign=Twitter+Website+Traffic News in breast oncology - year in review Powered by @VuMedi https://x.com/PTarantinoMD/status/1753124058407825823s=20&utm_source=twitter&utm_medium=social&utm_content=ce3dbc7e-ff47-4021-9aa6-2dda5d68274d&utm_campaign=Twitter+Website+Traffic News in breast oncology - year in review"
X Link 2024-02-01T20:49Z [----] followers, [----] engagements
"Dive into Prof. Lambertini's insights at #EBCC14 Satellite Symposium on #ESMO mBC guidelines. Explore endocrine resistance CDK4/6i in 1L & role of 2L 'classical' therapies like FUL monotherapy & everolimus combos. Find out more at: #MedEd @matteolambe https://cor2ed.com/breast-cancer-connect/programmes/ebcc-14-breast-cancer-treatments/ https://cor2ed.com/breast-cancer-connect/programmes/ebcc-14-breast-cancer-treatments/"
X Link 2024-04-03T10:06Z [----] followers, 336.5K engagements
"Missed @dradityabardia 's Tweetorial on treating HER2-low mBC: 2L and beyond No worries It is now available on-demand: Explore patient case discussions covering ESR1 and PIK3CA co-mutations TRAE management and post-2L treatment options. Don't miss out https://ow.ly/qBz250RiMSO https://ow.ly/qBz250RiMSO"
X Link 2024-04-18T08:32Z [----] followers, 1.5M engagements
"📢Hot off the press Trastuzumab deruxtecan shows anti-tumor activity in solid tumors with #HER2 mutations. Objective response rate: 29.4%. 51% experienced grade [--] or worse adverse events with 10% being drug-related serious events. #bcsm https://ow.ly/KlNJ50Rxeea https://ow.ly/KlNJ50Rxeea"
X Link 2024-05-07T07:39Z [----] followers, [---] engagements
"Looking forward to these highly anticipated trials to be presented at #ASCO24 Will you be there Less than a week to what promises to be a terrific ASCO24. Multiple trials with practice changing potential including with ADCs challenging our HER2 categories CDK4/6 inhibitors beyond progression adjuvant IO for TNBC and much more. See you in Chicago next week #bcsm #ASCO24 https://t.co/AWJby4PnPQ Less than a week to what promises to be a terrific ASCO24. Multiple trials with practice changing potential including with ADCs challenging our HER2 categories CDK4/6 inhibitors beyond progression"
X Link 2024-05-25T06:21Z [----] followers, [----] engagements
"How will endocrine therapy evolve in eBC A risk-based model presented by @FAndreMD at #SGBCC2025 highlights the hypothesised role of novel endocrine therapies including SERDs in eBC. All eyes are on upcoming trial results and their potential to shape future practice. #BreastCancer #Oncology Future of endocrine therapy in ebc in near future. View by @FAndreMD . #SGBCC2025 @OncoAlert @OncBrothers @TwoOncDocs @dr_yakupergun @stolaney1 @hoperugo @ErikaHamilton9 @darioT_ https://t.co/Xz9XSlpgND Future of endocrine therapy in ebc in near future. View by @FAndreMD . #SGBCC2025 @OncoAlert"
X Link 2025-03-12T14:02Z [----] followers, [----] engagements
"🚨 #SABCS23 is now accepting abstract Submit by July [--] and seize the opportunity to present your #BreastCancer focused research. Click bellow for more information: #MedEd #bcsm #oncology http://bit.ly/42tn6mJ http://bit.ly/42tn6mJ"
X Link 2023-05-16T17:47Z [----] followers, [----] engagements
"Want to learn more about new oral #ET options in ER+ #breastcancer Join the virtual discussion with our experts Dr Tolaney(@stolaney1) Dr Bardia(@dradityabardia) & Prof. Frdrique Penault-Llorca. 📅 [--] June 📍Online REGISTER NOW #MedEd #bcsm http://ow.ly/hFpe50OrXgm http://ow.ly/hFpe50OrXgm"
X Link 2023-05-19T14:00Z [----] followers, 552.1K engagements
"#SERDs: where are we Great presentation #ASCO23 by Dr. Hernando highlights: Elacestrant approved w/ positive phase [--] data Camizestrant shows promising phase [--] results Want to learn more REGISTER NOW and join the virtual event w/ our http://ow.ly/hFpe50OrXgm http://ow.ly/hFpe50OrXgm"
X Link 2023-06-03T15:56Z [----] followers, [----] engagements
"A population study presented at #ASCO23 by one of our wonderful experts @PTarantinoMD. Results suggested that the use of #chemotherapy is associated with 5-yrs breast cancer-specific survival in pts w/ T1c TNBC but NOT T1b #TNBC. #MedEd #bcsm #breastcancer"
X Link 2023-06-07T15:29Z [----] followers, [----] engagements
"Don't miss Dr Tarantino's (@PTarantinoMD) insightful review of the #NATALEE #SONIA & #TROPiCS-02 trials presented at #ASCO23 He discusses key data and their impact on #BC clinical practice. You can find all of COR2ED's ASCO23 updates here: #MedEd https://ow.ly/YCgs50OINCY https://ow.ly/YCgs50OINCY"
X Link 2023-06-08T10:27Z [----] followers, [----] engagements
"Catch Dr. Tarantino's (@PTarantinoMD) discerning review of #NATALEE #SONIA & #TROPiCS02 trials at #ASCO23 He discusses key data and their significance for #BC clinical practice. Find all ASCO23 updates from COR2ED here: #MedEd https://ow.ly/YCgs50OINCY https://ow.ly/YCgs50OINCY"
X Link 2023-06-13T08:28Z [----] followers, [----] engagements
"🔥1 day left to register BOOK YOUR PLACE NOW Hosted by Dr Tolaney (@stolaney1) Dr Bardia (@dradityabardia) and Prof. Penault-Llorca Join them in the online discussion on #oralSERDs for #ER+ advanced/metastatic #breastcancer #MedEd #bcsm #MBC https://ow.ly/nV6950ORxjj https://ow.ly/nV6950ORxjj"
X Link 2023-06-19T09:33Z [----] followers, [----] engagements
"Congratulations to @PTarantinoMD and co-authors for publishing a chapter on early-stage HER2+ breast cancer treatment in the 6th edition of Bland and Copeland's "The Breast" An invaluable resource for breast cancer research & treatment. 👏👏👏 #MedEd https://ow.ly/bI6h50ORBy9 https://ow.ly/bI6h50ORBy9"
X Link 2023-06-20T10:00Z [----] followers, [----] engagements
"Join clinicians from around the world at the 22nd Annual #InternationalBreastCancerCongress to discuss cutting edge treatments data and approaches that are driving the future of breast cancer therapy. 📆14-15 July #MedEd #oncology https://ow.ly/U9Zi50ORkvv https://ow.ly/U9Zi50ORkvv"
X Link 2023-06-30T09:00Z [----] followers, [----] engagements
"🔥Don't miss out Watch the replay of our latest expert knowledge share on #oralSERDs in ER+ #metastaticbreastcancer led by our esteemed experts: @stolaney1 @dradityabardia & Prof. Penault-Llorca. Now available on-demand➡ #MedEd #bcsm #ESR1 #webinar https://ow.ly/4muy50PfrEM https://ow.ly/4muy50PfrEM"
X Link 2023-07-18T17:09Z [----] followers, 616.6K engagements
"New #oncology research reveals that #HER2-low tumours could outperform HER2-zero tumours in OS but not in PFS. Lower rate of pCR found in HER2-low tumours vs. HER2-zero. #breastcancer #BC #MedEd https://ow.ly/XfHc50P90su https://ow.ly/XfHc50P90su"
X Link 2023-07-18T17:27Z [----] followers, [---] engagements
"Are #ADCs the answer to treating solid malignancies & HER2-pos. ABC Find out how researchers are refining ADC constructs to bring unprecedented clinical results & the pace of innovation in this field resulting in [--] regulatory approvals since [----] https://ow.ly/HRaR50PhQXA https://ow.ly/HRaR50PhQXA"
X Link 2023-07-21T08:55Z [----] followers, [----] engagements
"🚨NEW E-LEARNING AVAILABLE NOW Don't miss out on the opportunity to learn more about oral SERDs as a new therapy option for advanced & metastatic ER+/HER2- #BC w/ internationally renowned experts @stolaney1 @dradityabardia & Prof. Penault-Llorca. https://ow.ly/4BZw50PlIO8 https://ow.ly/4BZw50PlIO8"
X Link 2023-07-26T14:00Z [----] followers, [----] engagements
"🚨Introducing the 2nd episode of our 3-part podcast series on #oralSERDs in ER+ #BC Tune in to hear Drs Callahan & Dawood discuss two patient case studies & the intricacies of treatment selection. Listen now on COR2ED website: #MedEd #bcsm https://ow.ly/QlAf50Pnr5v https://ow.ly/QlAf50Pnr5v"
X Link 2023-07-28T12:03Z [----] followers, 796.2K engagements
"Exciting times ahead for #breastcancer oncology Check out this list of highly anticipated phase [--] trials to be presented at the upcoming medical congresses that can offer new possibilities for #BC practice in the foreseeable future🎗 👇👇👇 https://x.com/PTarantinoMD/status/1687179181874876417utm_source=twitter&utm_medium=social&utm_content=87c897e1-2384-4a03-a1d4-1519aa62f738&utm_campaign=Twitter+Website+Traffic With #ESMO23 and #SABCS23 approaching we may soon see the results from several potentially practice-changing trials in breast oncology. Heres a personal non-exhaustive selection of"
X Link 2023-08-04T15:48Z [----] followers, [----] engagements
"🚨📣Check out our new CME accredited e-learning on #oralSERDs 🎓Learn more about this new therapy option for advanced & metastatic ER+/HER2- #BC w/ internationally renowned experts @stolaney1 @dradityabardia & Prof. Penault-Llorca #MedEd #bcsm https://ow.ly/E3bN50PvPIz https://ow.ly/E3bN50PvPIz"
X Link 2023-08-09T13:40Z [----] followers, 442.5K engagements
"#ADCs are revolutionizing breast cancer treatment Novel ADCs now in the pipeline have the potential to target epitopes beyond #HER2 & #TROP2. Improving safety & efficacy of ADCs requires finding reliable predictive biomarkers. 👇👇👇 #MedEd #bcsm https://ow.ly/8ZUM50PzPcN https://ow.ly/8ZUM50PzPcN"
X Link 2023-08-20T10:05Z [----] followers, [----] engagements
"🚨📣Check out our brand-new accredited e-learning on oral #SERDs 🎓Learn more on this new therapy option for advanced & metastatic ER+/HER2- #BC w/ internationally renowned experts @stolaney1 @dradityabardia & Prof. Penault-Llorca #MedEd #bcsm https://ow.ly/5VhW50PJXv6 https://ow.ly/5VhW50PJXv6"
X Link 2023-09-13T08:01Z [----] followers, [----] engagements
"🚨Ready for an immersive experience Join oncology expert Dr @ElisaAgostinett in this innovative #interactive video & make key decisions throughout a patient journey with ER+/HER2- de novo #mBC. Head to our website & be part of the journey #MedEd https://cor2ed.com/breast-cancer-connect/programmes/advanced-breastcancer-interactive-case/ https://cor2ed.com/breast-cancer-connect/programmes/advanced-breastcancer-interactive-case/"
X Link 2023-09-21T20:53Z [----] followers, 846.3K engagements
"💡Embark on a innovative journey w/ expert Dr @ElisaAgostinett in our first #interactive patient case video Interact engage & unlock valuable insights thought-provoking questions & clickable resources at every turn🚀 #BreastCancerAwarenessMonth https://cor2ed.com/breast-cancer-connect/programmes/advanced-breastcancer-interactive-case/ https://cor2ed.com/breast-cancer-connect/programmes/advanced-breastcancer-interactive-case/"
X Link 2023-10-03T10:00Z [----] followers, [---] engagements
"Presidential session with Dr Bardia - a wonderful presentation on #TROPION- Breast01 Study meets primary end point (PFS) Dato-DXd vs ICC: 🔸Median PFS: [---] vs [---] months 🔸ORR: 36.4% vs 22.9% 🔸OS: not mature 🔸Most TRAEs were of grade 1-2 and manageable #ESMO23 #MedEd"
X Link 2023-10-23T14:51Z [----] followers, [---] engagements
"We are delighted to announce a 10-day #tweetorial hosted by Dr Tarantino coming on our page Nov 13th Here's how it works: 1Patient case presentation 2Answer [--] polling questions [---] hrs to answer each question 4Watch Dr Tarantino's tailored response #MedEd @PTarantinoMD"
X Link 2023-11-08T12:40Z [----] followers, 720.9K engagements
"#Tweetorial is now live Today's focus: Patient Case Presentation Meet Jane a [--] y.o. with ER+/HER2- de novo MBC. 1L treatment: Let + Ribo. Progression occurred [---] yrs post-initiation. Head to the main page to answer the first question you have 48hrs #MedEd @PTarantinoMD"
X Link 2023-11-13T14:00Z [----] followers, 12.9K engagements
"Question 2/5 is now closed Interesting to see votes were quite varied. Don't miss Dr @PTarantinoMD response video for some valuable insight on recent #ASCO23 guidelines. Find the 3rd question posted below in this #thread tackling CDK4/6i sequencing controversy #MedEd #bcsm"
X Link 2023-11-17T14:00Z [----] followers, [----] engagements
"Question 3/5 voting has now ended The votes clearly reflect the controversy surrounding the use of CDK4/6i in ER+ #mbc Watch Dr @PTarantinoMD response video as he gives his insights & reviews relevant studies You can now find question #4 below in this thread #MedEd #bcsm"
X Link 2023-11-19T14:01Z [----] followers, 12.2K engagements
"Question 4/5 is now closed As 2L treatment options evolve it's important to stay up to date w/ recent research Watch Dr. @PTarantinoMD response video as he discusses key data & current options for ER+ mBC Find the 5th & LAST #tweetorial question below in this #thread #bcsm"
X Link 2023-11-21T14:01Z [----] followers, 11.5K engagements
"Q5. Elacestrant was choosen for Jane's 2L treatment. What are the most frequently anticipated AEs during treatment Jane's case summary: [---] y.o with ER+/HER2- MBC 21L Treatment: Let + Ribo 3Progression: [---] yrs post treatment initiation 4Mutations: ESR1m Nausea & fatigue Diarrhea & dyspepsia Neutropenia & back pain Hyperglycemia & rash Nausea & fatigue Diarrhea & dyspepsia Neutropenia & back pain Hyperglycemia & rash"
X Link 2023-11-21T14:01Z [----] followers, 169K engagements
"Ever wondered what those fighting metastatic #BC go through daily Wish someone had guided you on supporting a loved one post-diagnosis Brace yourself for a deeply moving video series launching soon because: #BreastCancer doesn't end on the 31st of October. Stay tuned🎗"
X Link 2023-11-25T17:42Z [----] followers, [----] engagements
""Just listen to what your loved ones are saying. Just listen" Families supporting #BC patients may often struggle but advice is clear: Be there acknowledge the ongoing journey offer love & support. Remember: #BreastCancer doesn't end on October 31st @GRASPtweets #bcsm"
X Link 2023-11-29T09:24Z [----] followers, 223.3K engagements
""What is presented to a patient has an extreme effect on the future of their life" To #HCPs treating #BC this one is for you Amid hardships of treatment recognising pts as individuals & fostering education is crucial 🎗#BreastCancer doesn't end on October 31st @GRASPtweets"
X Link 2023-12-01T09:21Z [----] followers, 510.9K engagements
""Cancer is part of your life but it is not your entire life." In the final episode we ask pts: What advice would you give to your past selves Their responses deliver a powerful message: be kind to yourself trust love & live life to the full @GRASPtweets #bcsm #MedEd"
X Link 2023-12-03T08:57Z [----] followers, 247.2K engagements
"🚨 Missed the live Tweetorial by Dr Tarantino No worries You can now watch the on-demand video here: Join Dr @PTarantinoMD as he journeys through a ER+/HER2- #mBC case. Gain insights into biomarkers testing & personalized treatment options. #MedEd https://cor2ed.com/breast-cancer-connect/programmes/tweetorial-navigating-breastcancer/ https://cor2ed.com/breast-cancer-connect/programmes/tweetorial-navigating-breastcancer/"
X Link 2023-12-07T17:04Z [----] followers, 534.6K engagements
"Which 2L treatment would you choose for pts w/ #mBC & an ESR1m Test yourself & engage w/ our interactive patient case video series enriched by MCQs & clickable resources For Ep [--] Dr @ElisaAgostinett delves into the complexities of ER+ mBC #MedEd https://ow.ly/n3vJ50Qh2gs https://ow.ly/n3vJ50Qh2gs"
X Link 2023-12-11T11:39Z [----] followers, 265.1K engagements
"🚨Check out our [--] part #podcast series discussing oral #SERDs' efficacy & safety in ER+ #BreastCancer treatment selection & sequencing w/ Prof Dawood & Assoc. Prof Callahan Delve into four patient cases & explore current treatment challenges #MedEd https://ow.ly/bRGb50QhkQV https://ow.ly/bRGb50QhkQV"
X Link 2023-12-12T14:00Z [----] followers, 641.7K engagements
"Explore the top [--] takeaways from #SABCS23 with Dr @PTarantinoMD featuring insights on groundbreaking studies like #KATHERINE and #INAVO120. 👇 👇 👇 #MedEd #bcsm https://x.com/Sameh_VuMedi/status/1736878152616403356s=20 Check out Dr. Paolo Tarantino @PTarantinoMD @DFCI_BreastOnc discussing top [--] takeaways from #SABCS23 including KATHERINE & INAVO120 #bcsm #HER2 #TNBC #BreastCancer full📽on #VuMedi 👇 https://t.co/pg13y8v35Z https://t.co/36Npf8hD1C https://x.com/Sameh_VuMedi/status/1736878152616403356s=20 Check out Dr. Paolo Tarantino @PTarantinoMD @DFCI_BreastOnc discussing top [--] takeaways"
X Link 2023-12-21T08:01Z [----] followers, [----] engagements
"🚨 📢 Promising results from #CAPItello-291 trial in HR+/HER2 ABC: Adding #Capivasertib to #Fulvestrant boosts PFS significantly (HR 0.60; p0.001) with manageable AEs often low grade. Early intervention with medications proves effective. #MedEd #bcsm https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.1067role=tab https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.1067role=tab"
X Link 2023-12-22T09:00Z [----] followers, [---] engagements
"Study findings reveal that fixed-dose #capecitabine [----] mg twice daily on a 7/7 schedule demonstrates comparable survival and significantly lower toxicity in #MBC compared to standard BSA-based dosing. Read more about the X-7/7 trial: #MedEd https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.1007#::text=Conclusions%3A%20Fixed%20dose%20capecitabine%20 https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.1007#::text=Conclusions%3A%20Fixed%20dose%20capecitabine%20"
X Link 2024-01-12T15:00Z [----] followers, [----] engagements
"❓Which 2L treatment option would you recommend for patients w/ #mBC & an ESR1 mutation Challenge yourself w/ our interactive patient case video series with MCQs & clickable resources Episode 1: Dr. @ElisaAgostinett explores the intricacies of ER+ mBC https://cor2ed.com/breast-cancer-connect/programmes/advanced-breastcancer-interactive-case/utm_source=twitter&utm_medium=social&utm_content=53726c68-c9d7-4fa8-b10f-47e578a6ff20&utm_campaign=Twitter+Website+Traffic"
X Link 2024-01-16T11:43Z [----] followers, 571.2K engagements
"Great initiative @DFCI_BreastOnc has introduced #BreastCancer weekly digest for the latest breakthroughs in breast cancer research 👇 👇 👇 #MedEd #bcsm https://x.com/DFCI_BreastOnc/status/1747382786879615023s=20 Introducing the #BreastCancer Research Digest - a summary of last weeks publications from select high-impact journals (January 8th-14th 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch https://t.co/UdswlY5ELj https://x.com/DFCI_BreastOnc/status/1747382786879615023s=20 Introducing the #BreastCancer Research Digest - a summary of last weeks publications from select"
X Link 2024-01-20T11:56Z [----] followers, [----] engagements
"🚨Check out our [--] part #podcast series discussing oral #SERDs' efficacy & safety in ER+ #BreastCancer treatment selection & sequencing w/ Prof Dawood & Assoc. Prof Callahan Delve into four patient cases & explore current treatment challenges #MedEd https://ow.ly/ACWC50Qt2LR https://ow.ly/ACWC50Qt2LR"
X Link 2024-01-26T10:01Z [----] followers, [---] engagements
"📊 #monarchE Update: 96% PRO completion consistent QoL trends. Minor diarrhea diffs at [--] & [--] months. 69-78% report minimal side effects during treatment. Post-treatment PROs align confirming tolerable toxicity with adjuvant #abemaciclib. #MedEd https://ow.ly/IxFT50QsT2G https://ow.ly/IxFT50QsT2G"
X Link 2024-01-27T10:00Z [----] followers, [----] engagements
"For #WorldCancerDay our gratitude also goes to the dedicated experts who joined us in crafting educational programs supporting #HCPs' clinical decision making. Together we strive to advance healthcare knowledge & enhance patient-centered care #bcsm https://ow.ly/OqrX50QxBEC https://ow.ly/OqrX50QxBEC"
X Link 2024-02-04T20:04Z [----] followers, [----] engagements
"Ever heard of "scanxiety"❓ Your patients might be going through it. Save the date for this insightful event to discover ways you can provide crucial support. #MedEd #bcsm https://x.com/DFCI_BreastOnc/status/1752740521691480448s=20&utm_source=twitter&utm_medium=social&utm_content=afafa673-4eb9-4140-87cb-5db90e86d72c&utm_campaign=Twitter+Website+Traffic Join Sarah Sammons MD (@drsarahsam) and Jessica Mosey LICSW for a free #EMBRACE #MetastaticBreastCancer webinar on Staging Progression and Managing Scanxiety in #MBC. 🗓March [--] [----] 12-1 pm ET Register here🔽 https://t.co/EVYz93mcuY"
X Link 2024-02-08T10:01Z [----] followers, [----] engagements
"🧬 Wondering about the significance of #ESR1-mut testing during recurrence/PD on ET Look no further Discover our animated video where Prof. Bidard explores treatment & testing strategies for pts w/ mBC. #MedEd #bcsm https://ow.ly/FB7x50QCC5l https://ow.ly/FB7x50QCC5l"
X Link 2024-02-16T10:57Z [----] followers, 598.3K engagements
"Curious about the post-administration landscape of #elacestrant In this animated video Prof. Dieci (@vitti10) explores PRO data from #EMERALD strategies to manage AEs & #treatment options beyond 2L progression in pts w/ ER+ mBC Watch #MedEd https://cor2ed.com/breast-cancer-connect/programmes/er-breast-cancer-elacestrant/ https://cor2ed.com/breast-cancer-connect/programmes/er-breast-cancer-elacestrant/"
X Link 2024-02-29T11:09Z [----] followers, 394.6K engagements
"Delighted to announce a 10-day #tweetorial hosted by Dr Bardia coming on our page March 6th [--] days left Here's how it works 1Patient case presentation 2Answer [--] polling questions [---] hrs to answer each question 4Watch Dr Bardia's response videos #MedEd @dradityabardia"
X Link 2024-03-01T16:35Z [----] followers, 149.2K engagements
"10-day #tweetorial starts now Today's focus: Patient Case Presentation Case Summary: [--]. Amber [--] y.o. PMW with ER+/HER2-low mBC [--]. 1L Treatment: Abema + Ana [--]. PD: [---] yrs post-treatment Find Polling Q1/5 below in this thread - you have 48h #MedEd @dradityabardia"
X Link 2024-03-06T14:00Z [----] followers, 118.9K engagements
"@dradityabardia Q2/5 Tests detected PIK3CA & ESR1 mutations. Which 2L therapy would you choose for Amber Case Summary: [--]. [--] y.o. PMW with ER+/HER2-low mBC [--]. 1L Treatment: Abema + Ana [--]. PD: [---] yrs post-treatment Response video by @dradityabardia available in just 48h #MedEd Elacestrant Alpelisib + fulvestrant Fulvestrant Capecitabine Elacestrant Alpelisib + fulvestrant Fulvestrant Capecitabine"
X Link 2024-03-08T14:06Z [----] followers, 93.1K engagements
"@dradityabardia Q3/5 After [--] month of elacestrant Amber reports Grade [--] nausea during a routine clinical visit. What would you do Share your thoughts below Stay tuned for Dr. Bardias response in 48h. Hold drug until Grade [--] or baseline #MedEd #bcsm Reduce dose Hold & reduce dose Permanently discontinue Hold* & resume same dose Reduce dose Hold* & reduce dose Permanently discontinue Hold* & resume same dose"
X Link 2024-03-10T14:11Z [----] followers, 136.2K engagements
"@dradityabardia Thanks for participating in Q3/5 What are the current EMA dosing recommendations for managing AEs post-elacestrant Watch @dradityabardia's response as he uncovers current strategies Find Q4/5 below in this thread addressing AE management for ALP+FUL instead #MedEd"
X Link 2024-03-12T14:00Z [----] followers, 183.5K engagements
"@dradityabardia Q4/5 Alternate scenario: After [--] weeks on alpelisib+fulvestrant reports show signs of hyperglycemia with blood sugar level at [---] mg/dL. What would you do Dont miss Dr. @dradityabardia s response in just 48h Hold drug until Grade [--] or baseline #MedEd #bcsm No dose adjustment Hold & reduce dose Permanently discontinue Hold* & resume same dose No dose adjustment Hold* & reduce dose Permanently discontinue Hold* & resume same dose"
X Link 2024-03-12T14:03Z [----] followers, 171.7K engagements
"@dradityabardia Q5/5 After [--] months of 2L treatment Amber progresses & switches to oral capecitabine. After [--] more months she experiences another progression. What 4L treatment do you recommend (Amber's diagnosis: ER+/HER2-low mBC) Watch for @dradityabardia response video in 48h #MedEd Trastuzumab emtansine Trastuzumab deruxtecan Eribulin Sacituzumab govitecan Trastuzumab emtansine Trastuzumab deruxtecan Eribulin Sacituzumab govitecan"
X Link 2024-03-14T14:26Z [----] followers, 61.1K engagements
"What is the benefits of biomarker-selected endocrine-based therapies in ER+/HER2- mBC Join Prof. Guarneri as she summarizes her talk at the #EBCC14 Satellite Symposium addressing current and future landscape post CDK4/6i progression. Find out more at: #MedEd https://ow.ly/IXy450R7jRH https://ow.ly/IXy450R7jRH"
X Link 2024-04-03T10:13Z [----] followers, 487.5K engagements
"What is the clinical significance of ESR1m Tune in as Prof. Rojo gives an overview of his talk at the EBCC14 Satellite Symposium discussing predictive & prognostic value of ESR1m along with optimal testing strategies. Find out more at: #MedEd https://ow.ly/IXy450R7jRH https://ow.ly/IXy450R7jRH"
X Link 2024-04-03T10:23Z [----] followers, 449.6K engagements
"🌸🎗@TheLancet Breast Cancer Commission have put together a powerful road map addressing prevention personalized treatment collaboration and patient empowerment. Highly recommended reading for clinicians and patients alike. #bcsm #MedEd https://ow.ly/P5Hi50RjO4I https://ow.ly/P5Hi50RjO4I"
X Link 2024-04-21T13:10Z [----] followers, [---] engagements
"ADCs are transforming cancer treatment with [--] approved and [---] in development. Biomarkers are crucial for patient selection as ADC combination therapies evolve. Collaboration is key to advancing research and improving outcomes. #MedEd A good read: https://ow.ly/nGwP50Rkw2Y https://ow.ly/nGwP50Rkw2Y"
X Link 2024-04-28T09:00Z [----] followers, [---] engagements
"💥New study from @PTarantinoMD: T-DM1 resulted in 5-year iDFS of 97.0% and RFI of 98.3% with high overall and breast cancer-specific survival rates. HER2DX testing showed outcome variations by risk scores highlighting its role in #BC management. #MedEd https://x.com/PTarantinoMD/status/1807411372906447227 Is de-escalation of adjuvant treatment safe also in stage I HER2+ tumors larger than [--] cm ✅ In ATEMPT patients receiving T-DM1 had excellent 5-year iDFS (95%) irrespective of tumor size. https://t.co/CKOIkFIq9T https://t.co/oD3qrS5fO4 https://x.com/PTarantinoMD/status/1807411372906447227 Is"
X Link 2024-07-06T08:00Z [----] followers, [----] engagements
"❓Did you know Half of BRCA1/2 carriers are men but their risksprostate pancreatic and breast cancersare often overlooked. Genetic testing for men is crucial for early detection and treatment. 🚹 New article published in @JAMAOnc: #MedEd https://ow.ly/HZin50SNrCR https://ow.ly/HZin50SNrCR"
X Link 2024-08-02T08:01Z [----] followers, [---] engagements
"💭 How do CDK4/6i compare to PI3K/AKT/mTOR inhibitors in ER+/HER2- MBC In 7.8K patients CDK4/6i showed a median OS of 40.7m vs. 29.8m for PI3K/AKT/mTOR with higher PFS (14.8m vs. 8.3m) and ORR. CDK4/6i appear as strong first-line options. #MedEd https://ow.ly/1imn50SVr8H https://ow.ly/1imn50SVr8H"
X Link 2024-08-15T08:01Z [----] followers, [---] engagements
"❓Ever wondered how ctDNA & cutting-edge therapies are changing the game for ER+/HER2- metastatic #breastcancer Revisit our #Tweetorial with Dr. Paolo Tarantino & learn about Elacestrant for ESR1 mutations ctDNA & personalised treatment & more. https://ow.ly/TZM550SVemb https://ow.ly/TZM550SVemb"
X Link 2024-08-19T08:55Z [----] followers, [----] engagements
"🔁 Important findings from the #ATEMPT trial on Stage I HER2-positive #BreastCancer Explore the 5-year results comparing adjuvant Trastuzumab Emtansine vs. Paclitaxel + Trastuzumab. #MedEd Check out the full study below👇 https://x.com/DFCI_BreastOnc/status/1824841185908998351 Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive #BreastCancer: 5-Year Results and Correlative Analyses From #ATEMPT 👉https://t.co/5l3sVrg6Av @PTarantinoMD @stolaney1 @NabihahTayob @adawaksmd @awolff https://t.co/9QWmHXekxG"
X Link 2024-08-24T08:00Z [----] followers, [----] engagements
"🔥 Big news The ESMO [----] breast cancer abstract lineup is packed with new research and clinical trial data. Expect important updates that could change the way we treat breast cancer. Stay tuned https://x.com/dr_yakupergun/status/1828430544624836696 My Top [--] Breast Cancer Abstracts list at #ESMO24 👇 https://t.co/xbXsAidNrB https://x.com/dr_yakupergun/status/1828430544624836696 My Top [--] Breast Cancer Abstracts list at #ESMO24 👇 https://t.co/xbXsAidNrB"
X Link 2024-08-30T08:45Z [----] followers, [---] engagements
"❗ The latest breast cancer data from #ESMO24 ❗ Prof. Franois-Clment Bidard joined us in Barcelona to share his views on breast cancer data presented from KEYNOTE-522 DESTINYBreast-12 & NATALEE trials. Watch his video update 📺 #MedEd #OncTwitter #oncology"
X Link 2024-09-17T14:35Z [----] followers, [---] engagements
"📣 Breast cancer data from #ESMO24 📣 Prof. Franois-Clment Bidard shares his perspective on the latest breast cancer data from the KEYNOTE-522 DESTINYBreast-12 & NATALEE trial. Will they impact clinical practice Watch his video update 📺👇 #MedEd #OncTwitter #oncology https://cor2ed.com/n-connect/programmes/esmo-2024-lung-hcc-gi-breast-gu/media=6 https://cor2ed.com/n-connect/programmes/esmo-2024-lung-hcc-gi-breast-gu/media=6"
X Link 2024-09-24T18:57Z [----] followers, 270.8K engagements
"October is #BreastCancer Awareness Month [--] in [--] women are diagnosed with breast cancer but early detection boosts survival to 99% #MedEd helps turn science into life-saving care. Lets raise awareness and save lives Check out our resources: 🎗 https://ow.ly/hGF750TzRgO https://ow.ly/hGF750TzRgO"
X Link 2024-10-01T10:18Z [----] followers, [----] engagements
"🎗 It's #BreastCancerAwarenessMonth and we're proud to highlight our global network of medical experts Together we create #MedEd resources that help transform cutting-edge science into real-world practice advancing care & improving patient outcomes. https://ow.ly/wZhh50TCH17 https://ow.ly/wZhh50TCH17"
X Link 2024-10-04T10:17Z [----] followers, [----] engagements
"💡New insights on ILD during T-DXd treatment for HER2-positive cancers A case study reveals increased lung-derived cfDNA levels in ILD patients suggesting liquid biopsy could be key for monitoring ADC-related ILD. #MedEd https://ow.ly/aEzm50TF9Ie https://ow.ly/aEzm50TF9Ie"
X Link 2024-10-09T08:00Z [----] followers, [----] engagements
"How is the landscape of #biomarkertesting in HR+/HER2- metastatic #breastcancer evolving with liquid biopsy New #MedEd video 📺 👉 Pathologist Prof. Frdrique Penault-Llorca & medical oncologist Dr Aditya Bardia share their expert insights Find out more & download the slides: Supported by an Independent Educational Grant from Thermo Fisher Scientific. #MedEd #OncTwitter https://cor2ed.com/precision-oncology-connect/programmes/liquid-biopsy-metastatic-breast-cancer/ https://cor2ed.com/precision-oncology-connect/programmes/liquid-biopsy-metastatic-breast-cancer/"
X Link 2025-01-30T12:32Z [----] followers, 310K engagements
"📣 #ESMO Virtual Plenary [----] #breastcancer update Final OS results from the phase III TROPION-Breast01 trial ➡ From Prof. Franois-Clment Bidard and Dr @BarbaraPistill2 How will the latest Dato-DXd data impact treatment strategies for HR+/HER2 mBC 📺 Watch the video to find out Supported by an Independent Educational Grant from AstraZeneca #MedEd #Oncology"
X Link 2025-02-13T20:18Z [----] followers, 360K engagements
"❗Final OS results from the phase III TROPION-Breast01 trial 👉 This study evaluates datopotamab deruxtecan (Dato-DXd) versus chemotherapy in previously treated inoperable or metastatic HR+/HER2 BC. 📺 Watch the video for expert insights into data presented at #ESMO Virtual Plenary [----] See more: Supported by an Independent Educational Grant from AstraZeneca #MedEd #OncTwitter https://cor2ed.com/breast-cancer-connect/programmes/esmo-virtual-plenary-final-os-tropion-breast01/ https://cor2ed.com/breast-cancer-connect/programmes/esmo-virtual-plenary-final-os-tropion-breast01/"
X Link 2025-02-18T17:35Z [----] followers, 662.3K engagements
"➡ #BreastCancer update from an #ESMO Virtual Plenary Prof. Franois-Clment Bidard & Dr Barbara Pistilli share expert insights on the final OS results from the phase III TROPION-Breast01 trial They discuss: 🔸 Mechanism of action of Dato-DXd 🔸 TROPION-Breast01 PFS results & safety outcomes 🔸 Final overall survival results & their clinical implications 🔸 The future outlook for Dato-DXd See more: Supported by an Independent Educational Grant from AstraZeneca #MedEd #Oncology 📺 https://cor2ed.com/breast-cancer-connect/programmes/esmo-virtual-plenary-final-os-tropion-breast01/"
X Link 2025-02-27T20:29Z [----] followers, 265.8K engagements
"📣 The BCC team is heading to #SGBCC2025 Will you be there Lets connect Whether its diving into the latest research or catching up over coffee wed love to exchange insights on the evolving breast cancer treatment landscape. With so many critical discussions ahead were looking forward to hearing fresh perspectives exploring new data and engaging with the experts shaping the future of care. 💬 Reach out say hello and lets make the most of #SGBCC2025 together #BreastCancer #Oncology #MedEd"
X Link 2025-03-06T17:41Z [----] followers, [---] engagements
"📢 TROPION-Breast01 final OS results did not reach statistical significance; however subsequent ADC treatment may have influenced survival outcomes Find out more about the latest data presented at the ESMO Virtual Plenary [----] 👇 Supported by an Independent Educational Grant from AstraZeneca #MedEd #Oncology #BC 📷 https://cor2ed.com/breast-cancer-connect/programmes/esmo-virtual-plenary-final-os-tropion-breast01/ https://cor2ed.com/breast-cancer-connect/programmes/esmo-virtual-plenary-final-os-tropion-breast01/"
X Link 2025-03-11T17:55Z [----] followers, [---] engagements
"The evolving landscape of biomarker testing in HR+/HER2- metastatic #breastcancer and the role of liquid biopsy A #MedEd video from renowned experts 📺 More info + downloadable slides 👉 Supported by an Independent Educational Grant from Thermo Fisher Scientific. https://cor2ed.com/precision-oncology-connect/programmes/liquid-biopsy-metastatic-breast-cancer/ https://cor2ed.com/precision-oncology-connect/programmes/liquid-biopsy-metastatic-breast-cancer/"
X Link 2025-03-20T12:32Z [----] followers, 286.9K engagements
"🧬Precision oncology in HR+/HER2- metastatic #breastcancer. Dr Callahan and Dr Salgado discuss: Essential #biomarkers (ESR1m PIK3CA gBRCA) and their clinical implications Liquid vs tumour biopsy when and how Single gene vs broad panel testingand much more 📹 Watch the video highlights in this post 🗣Get the full conversation/listen to the audio on Spotify/Apple: Supported by an Independent Educational Grant from Thermo Fisher Scientific #MedEd #BCSM #OncTwitter https://cor2ed.com/precision-oncology-connect/programmes/molecular-testing-targeted-therapy-metastatic-breast-cancer/media=1"
X Link 2025-04-28T13:24Z [----] followers, 112.6K engagements
"What are the next therapeutic options for pts w/ pretreated HR+/HER2- (IHC 0) mBC who have developed endocrine resistance Discover how ADCs may offer a solution in this case-based video with Dr Barbara Pistilli. 📺 See more: Supported by an Independent Educational Grant from AstraZeneca. #MedEd #breastcancer #OncTwitter https://cor2ed.com/breast-cancer-connect/programmes/adcs-in-hr-her2-mbc/ https://cor2ed.com/breast-cancer-connect/programmes/adcs-in-hr-her2-mbc/"
X Link 2025-05-05T18:14Z [----] followers, 389.4K engagements
"📺 New case-based video on ADCs for HR+/HER2-metastatic #BreastCancer Dr Barbara Pistilli talks about: - The MoA of antibodydrug conjugates (ADCs) - ADCs currently available for HR+/HER2- mBC - Strategies for managing AEs Find out more 👇 Endorsed by @WarOnCancer @BiomarkerCo @GRASPtweets & Exon [--] Group Supported by an Independent Educational Grant from AstraZeneca. #MedEd #breastcancer #OncTwitter https://cor2ed.com/breast-cancer-connect/programmes/adcs-in-hr-her2-mbc/ https://cor2ed.com/breast-cancer-connect/programmes/adcs-in-hr-her2-mbc/"
X Link 2025-05-19T16:01Z [----] followers, [----] engagements
"📢#BreastCancer update from #ASCO25 Dr @PTarantinoMD shares breast cancer highlights from @ASCO and gives his take on data from SERENA-6 ASCENT-04/KEYNOTE-D19 DESTINY-Breast09 How will these data impact clinical practice 📺 Watch the video to find out See more updates from ASCO: #MedEd #OncMedEd #OncTwitter #BCSM https://cor2ed.com/n-connect/programmes/highlights-asco-2025/media=0 https://cor2ed.com/n-connect/programmes/highlights-asco-2025/media=0"
X Link 2025-06-03T15:33Z [----] followers, [----] engagements
"When and how can HCPs use liquid biopsy for #biomarker testing in HR+/HER2- metastatic #breastcancer ➡Which biomarkers do you test for ➡How do you use test results effectively Prof. Frdrique Penault-Llorca & Dr Aditya Bardia share their expert insights into this topic Watch the video below 📺 Find out more & download their slides: Supported by an Independent Educational Grant from Thermo Fisher Scientific. #MedEd #Oncology https://cor2ed.com/precision-oncology-connect/programmes/liquid-biopsy-metastatic-breast-cancer/"
X Link 2025-06-13T15:34Z [----] followers, 599.7K engagements
"How will the latest Dato-DXd data impact treatment strategies for HR+/HER2 mBC Prof. Franois-Clment Bidard & Dr @BarbaraPistill2 share expert insights on the latest TROPION-Breast01 update presenting the final OS results at the ESMO Virtual Plenary [----] 📺See more about this programme: Supported by an Independent Educational Grant from AstraZeneca https://cor2ed.com/breast-cancer-connect/programmes/esmo-virtual-plenary-final-os-tropion-breast01/ https://cor2ed.com/breast-cancer-connect/programmes/esmo-virtual-plenary-final-os-tropion-breast01/"
X Link 2025-07-30T14:20Z [----] followers, 219K engagements
"Managing ADC toxicities in HER2+ metastatic breast cancer spotlight on nausea & vomiting Nausea/vomiting are common AEs associated with ADCs particularly T-DXd along with fatigue. ILD while less common is an AE of special interest How can you manage N/V and more in clinical practice Get step-by-step guidance from Dr @stolaney1 Endorsed by @WarOnCancer Supported by an Independent Educational Grant from AstraZeneca"
X Link 2025-08-18T09:50Z [----] followers, 456K engagements
"How can we classify emetogenic risk & personalise antiemetic prophylaxis for HER2+ mBC patients receiving ADCs 📺Oncologist Dr Sara Tolany (@stolaney1) shines a light on ADC-induced nausea+vomiting and addresses the management of other adverse events such as fatigue and ILD Endorsed by @WarOnCancer Supported by an Independent Educational Grant from AstraZeneca #MedEd #OncTwitter #breastcancer"
X Link 2025-08-25T08:11Z [----] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing